China Pharma Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2018
Filed with the SEC on May 14, 2018 and accepted by EDGAR at May 14, 2018, 16:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-01-01 to 2018-03-31 | $3.6m | us-gaap:Revenues |
| Cost of revenue | 3 months2018-01-01 to 2018-03-31 | $2.6m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2018-01-01 to 2018-03-31 | $1.1m | us-gaap:GrossProfit |
| Research and development | 3 months2018-01-01 to 2018-03-31 | $22.2k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-01-01 to 2018-03-31 | −$140.7k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-01-01 to 2018-03-31 | $129.1k | us-gaap:InterestExpense |
| Income tax | 3 months2018-01-01 to 2018-03-31 | $26.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-01-01 to 2018-03-31 | −$293.5k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-01-01 to 2018-03-31 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2018-01-01 to 2018-03-31 | $523.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2018-01-01 to 2018-03-31 | $3.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-03-31 | $2.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-03-31 | $13.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-03-31 | $62.1m | us-gaap:Assets |
| Current liabilities | At period end2018-03-31 | $9.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-03-31 | $17.7m | us-gaap:Liabilities |
| Long-term debt | At period end2018-03-31 | $9.4m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2018-03-31 | $44.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-18-006100. Last ingested by Listed: Oct 30, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.